Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 EV-to-OCF is 109.06 as of Jul. 14, 2026, which is 35081% above its 10-year median of 0.31. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,410 Biotechnology companies, BLS Pharmaceuticals ranks worse than 97.38% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BLS Pharmaceuticals's Enterprise Value is A$220.84 Mil.
BLS Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.03 Mil. Therefore, BLS Pharmaceuticals's EV-to-OCF for today is 109.06.
The historical rank and industry rank for BLS Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ASX:BLS'
s EV-to-OCF Range Over the Past 10 Years
Min: -57.13 Med: 0.31 Max: 393.51
Current: 109.06
During the past 13 years, the highest EV-to-OCF of BLS Pharmaceuticals was 393.51. The lowest was -57.13. And the median was 0.31.
ASX:BLS's EV-to-OCF is ranked worse than 97.38% of 1410
companies
in the Biotechnology industry
Industry Median: -3.455
vs ASX:BLS: 109.06
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BLS Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
BLS Pharmaceuticals's share price for today is A$0.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.037.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BLS Pharmaceuticals EV-to-OCF Related Terms
BLS Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's EV-to-OCF falls into.
BLS Pharmaceuticals's current Enterprise Value is A$220.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a EV-to-OCF of 109.06 as of Jul. 14, 2026. This is 35081% above median its historical median of 0.31. According to the industry distribution chart, BLS Pharmaceuticals ranks #1373 out of 1410 companies in the Biotechnology industry, placing it in the top 97.4%.
Is BLS Pharmaceuticals' EV-to-OCF too high?
BLS Pharmaceuticals' current EV-to-OCF of 109.06 is 35081% above median its 10-year median of 0.31. Based on the distribution chart, BLS Pharmaceuticals ranks #1373 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' EV-to-OCF compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #1373 out of 1410 companies for EV-to-OCF. This places BLS Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BLS Pharmaceuticals's current EV-to-OCF is 109.06, which is 35081% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current EV-to-OCF is 109.06, which is 35081% above median its 10-year median of 0.31. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current EV-to-OCF is 109.06 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
EV-to-OCF: 109.06 (35081% above median its 10-year median of 0.31)
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
